MX367478B - Tratamiento de enfermedades colestasicas intrahepaticas. - Google Patents

Tratamiento de enfermedades colestasicas intrahepaticas.

Info

Publication number
MX367478B
MX367478B MX2016012203A MX2016012203A MX367478B MX 367478 B MX367478 B MX 367478B MX 2016012203 A MX2016012203 A MX 2016012203A MX 2016012203 A MX2016012203 A MX 2016012203A MX 367478 B MX367478 B MX 367478B
Authority
MX
Mexico
Prior art keywords
treatment
intrahepatic
diseases
cholestic
mbx
Prior art date
Application number
MX2016012203A
Other languages
English (en)
Other versions
MX2016012203A (es
Inventor
A Mcwherter Charles
Boudes Pol
Original Assignee
Cymaby Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymaby Therapeutics Inc filed Critical Cymaby Therapeutics Inc
Publication of MX2016012203A publication Critical patent/MX2016012203A/es
Publication of MX367478B publication Critical patent/MX367478B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Se proporciona un tratamiento de enfermedades colestásicas intrahepáticas por medio de terapia con MBX-8025 o una sal de MBX-8025.
MX2016012203A 2014-03-20 2015-03-19 Tratamiento de enfermedades colestasicas intrahepaticas. MX367478B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968037P 2014-03-20 2014-03-20
PCT/US2015/021502 WO2015143178A1 (en) 2014-03-20 2015-03-19 Treatment of intrahepatic cholestatic diseases

Publications (2)

Publication Number Publication Date
MX2016012203A MX2016012203A (es) 2017-01-19
MX367478B true MX367478B (es) 2019-08-23

Family

ID=52808186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012203A MX367478B (es) 2014-03-20 2015-03-19 Tratamiento de enfermedades colestasicas intrahepaticas.

Country Status (32)

Country Link
US (5) US9486428B2 (es)
EP (1) EP3119384B1 (es)
JP (1) JP6568577B2 (es)
KR (1) KR102000332B1 (es)
CN (1) CN106102734B (es)
AU (1) AU2015231232B2 (es)
BR (1) BR112016020260A8 (es)
CA (1) CA2941401C (es)
CL (1) CL2016002338A1 (es)
CY (1) CY1120927T1 (es)
DK (1) DK3119384T3 (es)
EA (1) EA032358B1 (es)
ES (1) ES2701094T3 (es)
FI (1) FIC20253004I1 (es)
FR (1) FR25C1031I1 (es)
HR (1) HRP20181914T1 (es)
HU (2) HUE041733T2 (es)
IL (1) IL247920B (es)
LT (2) LT3119384T (es)
MX (1) MX367478B (es)
NL (1) NL301338I2 (es)
NO (1) NO2025035I1 (es)
NZ (1) NZ724057A (es)
PH (1) PH12016501769B1 (es)
PL (1) PL3119384T3 (es)
PT (1) PT3119384T (es)
RS (1) RS57970B1 (es)
SI (1) SI3119384T1 (es)
SM (1) SMT201800690T1 (es)
UA (1) UA120756C2 (es)
WO (1) WO2015143178A1 (es)
ZA (1) ZA201606043B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045361A1 (en) 2008-10-17 2010-04-22 Metabolex, Inc. Methods of reducing small, dense ldl particles
US10272058B2 (en) * 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN106163508A (zh) 2014-04-11 2016-11-23 西玛贝医药公司 Nafld和nash的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3973959B8 (en) * 2017-09-26 2025-01-15 CymaBay Therapeutics, Inc. Treatment of cholestatic pruritus with seladelpar
WO2020102351A1 (en) * 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
CA3148602A1 (en) 2019-08-02 2021-02-11 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to tdp-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
DK4225291T3 (da) 2021-02-01 2024-05-27 Cymabay Therapeutics Inc Behandling af cholangiopati med seladelpar

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JP4293636B2 (ja) 1996-02-14 2009-07-08 アイシス・ファーマシューティカルス・インコーポレーテッド 糖修飾ギャップ付オリゴヌクレオチド
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
PL1667964T3 (pl) 2003-09-19 2010-01-29 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
ES2399721T5 (es) 2004-03-05 2016-05-25 Univ Pennsylvania Métodos para tratar trastornos o enfermedades asociados a la hiperlipidemia e hipercolesterolemia minimizando los efectos adversos
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
WO2010045361A1 (en) 2008-10-17 2010-04-22 Metabolex, Inc. Methods of reducing small, dense ldl particles
KR20130073884A (ko) 2010-03-30 2013-07-03 노파르티스 아게 Ｄｇａｔ1 억제제의 용도
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP3071198A1 (en) 2013-11-20 2016-09-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN106163508A (zh) 2014-04-11 2016-11-23 西玛贝医药公司 Nafld和nash的治疗
WO2015200580A1 (en) 2014-06-26 2015-12-30 Cymabay Therapeutics, Inc. Treatment of severe hypertriglyceridemia
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3973959B8 (en) 2017-09-26 2025-01-15 CymaBay Therapeutics, Inc. Treatment of cholestatic pruritus with seladelpar
AU2019378845A1 (en) 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
WO2020102351A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications

Also Published As

Publication number Publication date
FR25C1031I1 (fr) 2025-09-26
MX2016012203A (es) 2017-01-19
SI3119384T1 (sl) 2018-12-31
NZ724057A (en) 2018-09-28
US20150265560A1 (en) 2015-09-24
US9486428B2 (en) 2016-11-08
PH12016501769A1 (en) 2017-01-09
IL247920B (en) 2019-03-31
EA032358B1 (ru) 2019-05-31
SMT201800690T1 (it) 2019-01-11
US20210023031A1 (en) 2021-01-28
JP6568577B2 (ja) 2019-08-28
US20170014363A1 (en) 2017-01-19
NO2025035I1 (no) 2025-08-01
ES2701094T3 (es) 2019-02-20
US20180036268A1 (en) 2018-02-08
ZA201606043B (en) 2018-05-30
US10220011B2 (en) 2019-03-05
CA2941401A1 (en) 2015-09-24
EA201691887A1 (ru) 2017-03-31
DK3119384T3 (en) 2018-12-03
US10828273B2 (en) 2020-11-10
EP3119384A1 (en) 2017-01-25
HRP20181914T1 (hr) 2019-01-11
CA2941401C (en) 2019-06-11
US9808436B2 (en) 2017-11-07
KR102000332B1 (ko) 2019-07-15
CL2016002338A1 (es) 2017-04-21
NL301338I2 (nl) 2025-09-11
BR112016020260A8 (pt) 2021-06-29
FIC20253004I1 (fi) 2025-07-31
BR112016020260A2 (pt) 2017-08-15
KR20160125424A (ko) 2016-10-31
RS57970B1 (sr) 2019-01-31
AU2015231232A1 (en) 2016-09-22
PL3119384T3 (pl) 2019-03-29
PH12016501769B1 (en) 2017-01-09
EP3119384B1 (en) 2018-09-12
WO2015143178A1 (en) 2015-09-24
US20190192459A1 (en) 2019-06-27
HUS2500033I1 (hu) 2025-09-28
CN106102734A (zh) 2016-11-09
CN106102734B (zh) 2019-05-14
AU2015231232B2 (en) 2018-08-02
JP2017508817A (ja) 2017-03-30
LTPA2025529I1 (es) 2025-08-25
PT3119384T (pt) 2018-12-12
CY1120927T1 (el) 2019-12-11
HUE041733T2 (hu) 2019-05-28
UA120756C2 (uk) 2020-02-10
US11406611B2 (en) 2022-08-09
LT3119384T (lt) 2018-11-26

Similar Documents

Publication Publication Date Title
MX2016012203A (es) Tratamiento de enfermedades colestasicas intrahepaticas.
MX369921B (es) Tratamiento de la hgna y ehna.
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
IL249065A0 (en) Combination therapies for the treatment of cancer
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
LT3556775T (lt) Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
DK3134530T3 (da) Behandling af hyperbilirubinæmi
ECSP17015977A (es) Terapia de combinacion
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
EP3186010A4 (en) IMMERSIVE SHOWER HEAD
EP3448263A4 (en) Electrotherapeutic treatment
HUE053744T2 (hu) A rák kombinált kezelése
MX392537B (es) Tratamiento del prurito colestasico.
HUE053443T2 (hu) Heteroaril vegyületek szembetegségek kezelésére
FI20145484A7 (fi) Anodiliejun hydrometallurginen käsittely
DK2897382T3 (da) Forbedring af binaural kilde
IL257764B (en) Methods for treatment of diseases
DK3151814T3 (da) Behandling af en hudlæsion
MX2018014915A (es) Tratamiento de enfermedades colestasicas intrahepaticas.
PL3160913T3 (pl) Sposób oczyszczania osadu biologicznego
DK3182980T3 (da) Behandling af glykosyleringsmangelsygdomme
DK3200783T3 (da) Behandling af erytromelalgi
GB201410407D0 (en) Treatment of chagas disease
PL3903774T3 (pl) N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych
DK2975004T3 (da) Syrespildevandsbehandling

Legal Events

Date Code Title Description
FG Grant or registration